Figure 6.

Anlotinib treatments promoted the polarization of tumor associated macrophages (TAMs) from an M2- to an M1-like phenotype in myeloma PDXs. Tumor-bearing NDG mice were prepared and treated with anlotinib or vehicle control as described in Figure 4. Tumors at the end of treatments were excised and the single cell suspensions were prepared for flow cytometry. The aggregated events and dead cells were gated out. (A, B) Representative images and the quantification of tumor-associated macrophages (TAMs) in myeloma PDX1 and PDX2. (C, D) Representative images and the quantification of TAM subsets in myeloma PDX1 and PDX2. TAMs: CD45⁺CD11b⁺Gr1^-F4/80⁺, CD11c⁺CD206^-: CD45⁺CD11b⁺Gr1^-F4/80⁺CD11c⁺CD206^-, CD11c^-CD206⁺: CD45⁺CD11b⁺Gr1^-F4/80⁺CD11c^-CD206⁺, CD86⁺CD206^-: CD45⁺CD11b⁺Gr1^-F4/80⁺CD86⁺CD206^-, CD86^-CD206⁺: CD45⁺CD11b⁺Gr1^-F4/80⁺CD86^-CD206⁺. PDXs, patient-derived xenografts; Ctr, control group; Anlo, anlotinib treatment group. Significance was determined by unpaired two-tailed Student’s t-test. Data were from one experiment representative of two independent experiments with similar results. All data were presented as means ± SD. * P < 0.05, ** P < 0.01.